These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17224848)

  • 1. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.
    Klein CE; Chiu YL; Awni W; Zhu T; Heuser RS; Doan T; Breitenbach J; Morris JB; Brun SC; Hanna GJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):401-10. PubMed ID: 17224848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
    Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
    J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
    Rackley RJ
    J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.
    Garren KW; Rahim S; Marsh K; Morris JB
    J Pharm Sci; 2010 Feb; 99(2):626-31. PubMed ID: 19230020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
    Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
    J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
    Else LJ; Douglas M; Dickinson L; Back DJ; Khoo SH; Taylor GP
    Antimicrob Agents Chemother; 2012 Feb; 56(2):816-24. PubMed ID: 22106215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules.
    Tippabhotla SK; Thudi NR; Raghuvanshi R; Khuroo AH; Gurule S; Mishra S; Monif T; Lao VK
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):204-10. PubMed ID: 18397695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.
    Hill A; van der Lugt J; Sawyer W; Boffito M
    AIDS; 2009 Nov; 23(17):2237-45. PubMed ID: 19809270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
    Chachad S; Gogtay J; Malhotra G; Purandare S
    J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
    [No Abstract]   [Full Text] [Related]  

  • 13. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
    Ofotokun I; Chuck SK; Binongo JN; Palau M; Lennox JL; Acosta EP
    J Clin Pharmacol; 2007 Aug; 47(8):970-7. PubMed ID: 17615254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
    van der Flier M; Verweel G; van der Knaap LC; van Jaarsveld P; Driessen GJ; van der Lee M; Hartwig NG; Burger DM
    Antivir Ther; 2008; 13(8):1087-90. PubMed ID: 19195335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
    Zhang C; Denti P; Decloedt E; Maartens G; Karlsson MO; Simonsson US; McIlleron H
    Br J Clin Pharmacol; 2012 May; 73(5):758-67. PubMed ID: 22126409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
    Morello J; Soriano V; Blanco F; Rubio AJ; Jiménez-Nácher I; Rodríguez-Nóvoa S
    Drug Metab Lett; 2009 Apr; 3(2):67-9. PubMed ID: 19601866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.